Literature DB >> 18998239

Intravascular ultrasound assessment of coronary artery involvement in Fabry disease.

T Kovarnik1, G S Mintz, D Karetova, J Horak, J Bultas, R Skulec, H Skalicka, M Aschermann, M Elleder, A Linhart.   

Abstract

AIM: We used intravascular ultrasound (IVUS) to characterize coronary artery involvement in patients with Fabry disease (FD).
METHODS: Nine FD patients (5 women) were matched to 10 control patients (5 women) chosen from our IVUS database. Standard volumetric IVUS analyses were performed along with assessment of plaque echodensity.
RESULTS: Plaques in FD patients were diffuse and hypoechogenic compared with more focal and more echogenic lesions in control patients. Echogenicity of plaques was significantly lower in FD patients (median 30.7 +/- 12.9 vs 55.9 +/- 15.7, p = 0.0052, mean 37.2 +/- 15.6 vs 66.2 +/- 13.3, p = 0.0014). Diffusiveness was assessed as differences between mean and median plaque burden versus the plaque burden in each of the analysed cross-sections. These differences were lower in FD vs controls (5.8 +/- 4.8 vs 8.7 +/- 6.6, p < 0.001 for mean, and 5.8 +/- 4.9 vs 8.8 +/- 7.3, p < 0.001 for median) indicating a more diffuse involvement. The occurrence of lipid cores was significantly higher in FD patients than in controls (2.4 +/- 1.5 vs 1.0 +/- 0.94, p = 0.02).
CONCLUSION: IVUS showed diffuse hypoechogenic plaques in patients with FD. The explanation may be higher lipid content in plaques and accumulation of glycosphingolipid in smooth-muscle and endothelial cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18998239     DOI: 10.1007/s10545-008-0794-0

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  30 in total

Review 1.  American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound Studies (IVUS). A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents.

Authors:  G S Mintz; S E Nissen; W D Anderson; S R Bailey; R Erbel; P J Fitzgerald; F J Pinto; K Rosenfield; R J Siegel; E M Tuzcu; P G Yock
Journal:  J Am Coll Cardiol       Date:  2001-04       Impact factor: 24.094

2.  Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy.

Authors:  D F Moore; L T Scott; M T Gladwin; G Altarescu; C Kaneski; K Suzuki; M Pease-Fye; R Ferri; R O Brady; P Herscovitch; R Schiffmann
Journal:  Circulation       Date:  2001-09-25       Impact factor: 29.690

3.  Enhanced endothelium-dependent vasodilation in Fabry disease.

Authors:  G Altarescu; D F Moore; R Pursley; U Campia; S Goldstein; M Bryant; J A Panza; R Schiffmann
Journal:  Stroke       Date:  2001-07       Impact factor: 7.914

4.  Impaired myocardial perfusion reserve but preserved peripheral endothelial function in patients with Fabry disease.

Authors:  R J Kalliokoski; K K Kalliokoski; J Sundell; E Engblom; M Penttinen; I Kantola; O T Raitakari; J Knuuti; P Nuutila
Journal:  J Inherit Metab Dis       Date:  2005       Impact factor: 4.982

5.  Increased carotid intima-media thickness in the absence of atherosclerotic plaques in an adult population with Fabry disease.

Authors:  Frédéric Barbey; Noureddine Brakch; Ales Linhart; Xavier Jeanrenaud; Thomas Palecek; Jan Bultas; Michel Burnier; Daniel Hayoz
Journal:  Acta Paediatr Suppl       Date:  2006-04

6.  An atypical variant of Fabry's disease with manifestations confined to the myocardium.

Authors:  W von Scheidt; C M Eng; T F Fitzmaurice; E Erdmann; G Hübner; E G Olsen; H Christomanou; R Kandolf; D F Bishop; R J Desnick
Journal:  N Engl J Med       Date:  1991-02-07       Impact factor: 91.245

7.  Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease.

Authors:  Jaymin S Shah; Derralynn A Hughes; Bhavesh Sachdev; Maite Tome; Deirdre Ward; Philip Lee; Atul B Mehta; Perry M Elliott
Journal:  Am J Cardiol       Date:  2005-09-15       Impact factor: 2.778

8.  Correlation of intracoronary ultrasound plaque characteristics in atherosclerotic coronary artery disease patients with clinical variables.

Authors:  Q Rasheed; R Nair; H Sheehan; J M Hodgson
Journal:  Am J Cardiol       Date:  1994-04-15       Impact factor: 2.778

9.  Sequelae of storage in Fabry disease--pathology and comparison with other lysosomal storage diseases.

Authors:  M Elleder
Journal:  Acta Paediatr Suppl       Date:  2003-12

10.  Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase A.

Authors:  P M Elliott; H Kindler; J S Shah; B Sachdev; O E Rimoldi; R Thaman; M T Tome; W J McKenna; P Lee; P G Camici
Journal:  Heart       Date:  2005-08-05       Impact factor: 5.994

View more
  8 in total

Review 1.  Narrative review on Morbus Fabry: diagnosis and management of cardiac manifestations.

Authors:  Aleš Linhart; Tomáš Paleček
Journal:  Cardiovasc Diagn Ther       Date:  2021-04

Review 2.  Role of PET to evaluate coronary microvascular dysfunction in non-ischemic cardiomyopathies.

Authors:  Paco E Bravo; Marcelo F Di Carli; Sharmila Dorbala
Journal:  Heart Fail Rev       Date:  2017-07       Impact factor: 4.214

3.  Carotid intima-media thickness is increased in patients with treated mucopolysaccharidosis types I and II, and correlates with arterial stiffness.

Authors:  Raymond Y Wang; Elizabeth A Braunlin; Kyle D Rudser; Donald R Dengel; Andrea M Metzig; Kelly K Covault; Lynda E Polgreen; Elsa Shapiro; Julia Steinberger; Aaron S Kelly
Journal:  Mol Genet Metab       Date:  2013-11-12       Impact factor: 4.797

Review 4.  Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and management.

Authors:  Elizabeth A Braunlin; Paul R Harmatz; Maurizio Scarpa; Beatriz Furlanetto; Christoph Kampmann; James P Loehr; Katherine P Ponder; William C Roberts; Howard M Rosenfeld; Roberto Giugliani
Journal:  J Inherit Metab Dis       Date:  2011-07-09       Impact factor: 4.982

Review 5.  Cardiac abnormalities in Anderson-Fabry disease and Fabry's cardiomyopathy.

Authors:  R P Morrissey; K J Philip; E R Schwarz
Journal:  Cardiovasc J Afr       Date:  2011 Jan-Feb       Impact factor: 1.167

6.  Serum Bilirubin Levels and Promoter Variations in HMOX1 and UGT1A1 Genes in Patients with Fabry Disease.

Authors:  Alena Jirásková; Giulia Bortolussi; Gabriela Dostálová; Lenka Eremiášová; Lubor Golaň; Vilém Danzig; Aleš Linhart; Libor Vítek
Journal:  Oxid Med Cell Longev       Date:  2017-08-16       Impact factor: 6.543

Review 7.  Fabry disease: recent advances in pathology, diagnosis, treatment and monitoring.

Authors:  Björn Hoffmann
Journal:  Orphanet J Rare Dis       Date:  2009-10-11       Impact factor: 4.123

Review 8.  Anderson-Fabry disease in heart failure.

Authors:  M M Akhtar; P M Elliott
Journal:  Biophys Rev       Date:  2018-06-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.